Evaluation of Drug Candidates for Preclinical Development: Pharmacokinetics, Metabolism, Pharmaceutics, and Toxicology

Author:   Chao Han ,  Charles B. Davis ,  Binghe Wang (Georgia State University, Atlanta)
Publisher:   John Wiley & Sons Inc
ISBN:  

9780470044919


Pages:   304
Publication Date:   28 January 2010
Format:   Hardback
Availability:   Out of stock   Availability explained
The supplier is temporarily out of stock of this item. It will be ordered for you on backorder and shipped when it becomes available.

Our Price $238.95 Quantity:  
Add to Cart

Share |

Evaluation of Drug Candidates for Preclinical Development: Pharmacokinetics, Metabolism, Pharmaceutics, and Toxicology


Add your own review!

Overview

Emphasizes the integration of major areas of drug discovery and their importance in candidate evaluation It is believed that selecting the ""right"" drug candidate for development is the key to success. In the last decade, pharmaceutical R&D departments have integrated pharmacokinetics and drug metabolism, pharmaceutics, and toxicology into early drug discovery to improve the assessment of potential drug compounds. Now, Evaluation of Drug Candidates for Preclinical Development provides a complete view and understanding of why absorption-distribution-metabolism-excretion-toxicology (ADMET) plays a pivotal role in drug discovery and development. Encompassing the three major interrelated areas in which optimization and evaluation of drug developability is most critical—pharmacokinetics and drug metabolism, pharmaceutics, and safety assessment—this unique resource encourages integrated thinking in drug discovery. The contributors to this volume: Cover drug transporters, cytochrome P-450 and drug-drug interactions, plasma protein binding, stability, drug formulation, preclinical safety assessment, toxicology, and toxicokinetics Address developability issues that challenge pharma companies, moving beyond isolated experimental results Reveal connections between the key scientific areas that are critical for successful drug discovery and development Inspire forward-thinking strategies and decision-making processes in preclinical evaluation to maximize the potential of drug candidates to progress through development efficiently and meet the increasing demands of the marketplace Evaluation of Drug Candidates for Preclinical Development serves as an introductory reference for those new to the pharmaceutical industry and drug discovery in particular. It is especially well suited for scientists and management teams in small- to mid-sized pharmaceutical companies, as well as academic researchers and graduate students concerned with the practical aspects related to the evaluation of drug developability.

Full Product Details

Author:   Chao Han ,  Charles B. Davis ,  Binghe Wang (Georgia State University, Atlanta)
Publisher:   John Wiley & Sons Inc
Imprint:   John Wiley & Sons Inc
Dimensions:   Width: 16.00cm , Height: 2.10cm , Length: 24.10cm
Weight:   0.562kg
ISBN:  

9780470044919


ISBN 10:   0470044918
Pages:   304
Publication Date:   28 January 2010
Audience:   Professional and scholarly ,  Professional & Vocational
Format:   Hardback
Publisher's Status:   Active
Availability:   Out of stock   Availability explained
The supplier is temporarily out of stock of this item. It will be ordered for you on backorder and shipped when it becomes available.

Table of Contents

Reviews

In conclusion, the book brings the areas of ADME, toxicology and pharmaceutical science together to describe the approaches used to select safe compounds with the required pharmacokinetic and physiochemical properties for progressing into clinical development . (British Toxicology Society, Winter 2010)


This is a useful reference source for those new to, or aspiring to join the pharmaceutical industry, for academics, and for students of pharmacy and pharmaceutical sciences. (Chromatographia, 1 December 2010) In conclusion, the book brings the areas of ADME, toxicology and pharmaceutical science together to describe the approaches used to select safe compounds with the required pharmacokinetic and physiochemical properties for progressing into clinical development . (British Toxicology Society, Winter 2010)


In conclusion, the book brings the areas of ADME, toxicology and pharmaceutical science together to describe the approaches used to select safe compounds with the required pharmacokinetic and physiochemical properties for progressing into clinical development. (British Toxicology Society, Winter 2010)


Author Information

Chao Han, PHD, is Associate Director of Pharmacokinetics, Modeling and Simulation, Clinical Pharmacology Sciences, Centocor R&D. He has been working in drug discovery and early development for more than ten years, published over thirty research articles in peer-reviewed journals, and written three book chapters. Charles B. Davis, PHD, heads Drug Metabolism and Pharmacokinetics for the cancer Metabolism Drug Discovery Unit within Cancer Research at GlaxoSmithKline. He has more than twenty years experience in preclinical and clinical development and has served on the leadership teams of three of GSK's Centers of Excellence in Drug Discovery. Binghe Want, PHD, is Professor and Georgia research Alliance Eminent Scholar in Drug Discovery in the Department of Chemistry, Georgia State University and Georgia cancer Coalition Distinguished Scientist. He also serves as editor in chief of Medicinal research Reviews and is lead editor of Drug Delivery: Principles and Applications (Wiley).

Tab Content 6

Author Website:  

Customer Reviews

Recent Reviews

No review item found!

Add your own review!

Countries Available

All regions
Latest Reading Guide

MRG2025CC

 

Shopping Cart
Your cart is empty
Shopping cart
Mailing List